<?xml version="1.0" encoding="UTF-8"?>
<p id="par0085">Dyslipidemia was another independent variable associated with developing potential interactions with LPV/r in our study. Simvastatin and atorvastatin were 2 of the drugs with the highest rate of interaction, responsible for the previous association. Hypercholesterolemia and PI-statin interaction are also recurrent in HIV patients.
 <xref rid="bib0105" ref-type="bibr">
  <sup>21</sup>
 </xref> On the other hand, there is currently not enough evidence to show that statins are beneficial or harmful in COVID-19. Therefore, because prior cardiovascular disease is associated with a worse prognosis of COVID-19,
 <xref rid="bib0110" ref-type="bibr">
  <sup>22</sup>
 </xref> the immunomodulatory capacity of statins in the immune response
 <xref rid="bib0115" ref-type="bibr">
  <sup>23</sup>
 </xref> and their prior benefit in viral pneumonia,
 <xref rid="bib0120" ref-type="bibr">
  <sup>24</sup>
 </xref> it may be possible to consider keeping statins as indicated, by adjusting the dose or selecting those that are free of interaction with LPV/r (
 <xref rid="tbl0015" ref-type="table">Table 3</xref>).
</p>
